Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02792036
Other study ID # iRET
Secondary ID NCI-2016-00848
Status Completed
Phase Phase 1
First received
Last updated
Start date November 1, 2016
Est. completion date October 4, 2019

Study information

Verified date February 2020
Source St. Jude Children's Research Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Retinoblastoma (RB) is the most common intraocular tumor of childhood. Recurrent or refractory disease following therapy most often occurs due to persistence of vitreous disease and/or retinal reactivation of the main tumor mass. With this treatment protocol, investigators seek to identify a less invasive method of local drug delivery that does not disrupt the eye's integrity.

PRIMARY OBJECTIVE:

- To determine the safety and toxicity profile associated with intravitreal carboplatin for the treatment of recurrent or progressive intraocular retinoblastoma with vitreous seeding.

SECONDARY OBJECTIVES:

- To estimate the ocular salvage rate after treatment with intravitreal carboplatin in patients with recurrent or progressive intraocular retinoblastoma with vitreous seeding.

- To evaluate the effects of intravitreal carboplatin therapy on the histopathology of eyes enucleated for progressive or recalcitrant disease while on therapy.


Description:

The eye(s) will be sterilized prior to injection. Aqueous fluid (0.1-0.15ml) will be withdrawn and sent for pathology review. Carboplatin diluted in normal saline will be administered via intravitreal injection under anesthesia once to each eligible eye approximately every 14 days. Following the injection, triple freeze/thaw cryotherapy is applied to the injection site and the eye is washed with water. The eye is gently "shaken" in all directions to evenly distribute the drug.

This trial will use a traditional phase I design for dose de-escalation with two dose levels. The first 6 patients will be enrolled at dose level 1 and will be observed for dose-limiting toxicity (DLT) throughout the treatment period up to approximately 5 months after start of therapy. If 0-2 (of the first 6) participants experience DLT, a second cohort of 6 patients will be enrolled at the same dose level 1. Study accrual would be completed at 12.

However, if 3 or more of the first 6 patients experience DLT at dose level 1, the dose level would be de-escalated to level -1 and 6 patients enrolled at this level (dose -1). If 0-2 patients experience DLT at dose level -1, a second cohort of 6 patients will be enrolled at dose level -1, and the study accrual would be complete. If 3 or more patients experience DLT at dose level -1, accrual would also be complete.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date October 4, 2019
Est. primary completion date October 4, 2019
Accepts healthy volunteers No
Gender All
Age group N/A to 17 Years
Eligibility Inclusion Criteria:

- Refractory or recurrent retinoblastoma with vitreous seeding meeting eligibility criteria by ultrasonic biomicroscopy performed during examination under anesthesia (EUA) by an ophthalmologist:

- At least three consecutive clock hours of disease-free, attached peripheral retina through which the intraocular injection may be administered.

- Absence of invasion in anterior and posterior chamber.

- Absence of anterior hyaloid detachment.

- Absence of retinal detachment at the entry site.

- Absence of tumor at the entry site.

- ECOG Performance Score must be = 2 within two weeks prior to registration.

- Participants must have an adequate liver function, as defined by bilirubin =3 x upper limit of normal (ULN), and SGOT and SGPT =3 x ULN.

- Participants must have adequate renal function as defined by serum creatinine =3 x ULN for age.

- Legal guardians must sign an informed consent indicating that they are aware of this study, the possible benefits, and toxic side effects. Legal guardians will be given a signed copy of the consent form.

Exclusion Criteria:

- Presence of metastatic disease or gross orbital involvement.

- Participants must not have an invasive infection at time of protocol entry.

- Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Carboplatin
Carboplatin will be given intravitreally. Participants are eligible to receive up to 8 injections per eye (once approximately every 14 days) based on lack of toxicity and evidence of tumor response. An injection of consolidation will be given once a complete response is observed. If further regression of "stable" seeds is noted, additional injections (up to 8 maximum per eye) will be provided at the discretion of the treating team. Injections could be repeated if vitreous recurrence occurs from another source (and patient has not reached 8 max limit per eye).
Maxitrol®
Maxitrol® contains neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension and is for topical ophthalmic use only. It will be given for continued use for five days following the carboplatin injection to prevent infection.
Procedure:
Focal Therapy
Simultaneously with intravitreal carboplatin, focal therapy will be applied as needed to eradicate the retinal source of the seeding as well as all epiretinal and subretinal active tumors at the discretion of the treating ocular oncologist.
Plaque Radiotherapy
Participants who have developed progressive disease despite focal (non-irradiative) therapy will receive brachytherapy determined by consensus between the treating ophthalmologist and radiation oncologist.

Locations

Country Name City State
United States St. Jude Children's Research Hospital Memphis Tennessee

Sponsors (1)

Lead Sponsor Collaborator
St. Jude Children's Research Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants who develop dose-limiting toxicity (DLT) DLTs are defined as any of the following: uveitis, sterile or infectious endophthalmitis, retinopathy or rhegmatogenous retinal detachment, massive vitreous hemorrhage that obscures direct visualization of the retina/tumor, and/or cataract that threatens the visual axis or view by treating physician.
Grade 3 or 4 allergic reactions should lead to discontinuation of intravitreal carboplatin injections. Patients who have grade 3 or 4 allergic reactions will not be evaluable for this objective and will be replaced.
From baseline through end of therapy (up to 5 months)
See also
  Status Clinical Trial Phase
Recruiting NCT04564521 - Nitroglycerin for Intra-arterial Chemotherapy in Pediatric Retinoblastoma. N/A
Recruiting NCT02933333 - G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Phase 4
Withdrawn NCT01151748 - Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma Phase 2
Completed NCT01048892 - Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Phase 1
Active, not recruiting NCT00360750 - Chemotherapy With or Without Radiation Therapy or Observation in Treating Young Patients With Advanced Retinoblastoma Who Have Undergone Surgery to Remove the Eye N/A
Completed NCT00003173 - High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Phase 2
Enrolling by invitation NCT06227962 - Cognitive Functioning and Health Related Quality of Life in Retinoblastoma Survivors
Completed NCT01661400 - Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors Phase 1
Terminated NCT02617862 - PCI Imaging System in Pediatric Ophthalmology N/A
Recruiting NCT02329002 - SPT Screening in Irradiated Hereditary Retinoblastoma Survivors N/A
Terminated NCT01466855 - A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma Early Phase 1
Completed NCT01505569 - Auto Transplant for High Risk or Relapsed Solid or CNS Tumors N/A
Completed NCT00002515 - Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer Phase 2
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Completed NCT06367569 - Evaluation of MRI of the Pineal Gland in Retinoblastoma
Completed NCT02193724 - Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma
Completed NCT01884194 - Morphological Analysis of the Pineal Gland in Pediatric Retinoblastoma Patients Using Magnetic Resonance Imaging N/A
Terminated NCT01393769 - Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage Phase 2
Completed NCT00006246 - Busulfan in Treating Children and Adolescents With Refractory CNS Cancer Phase 1
Terminated NCT00003926 - Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors Phase 1